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Comment: Stent thrombosis may relate to impaired or delayed re-
endothelialization secondary to the drug-eluting properties of the stent.
Regardless of cause, sudden thrombosis of coronary artery stents is now
recognized as having a highmortality rate, likely because of abrupt occlusion
of an otherwise widely patent coronary artery. Of the potential variables
influencing stent thrombosis, it appears that cessation of clopidogrel therapy
is the risk factor that both the patient and physician can modify. More work
will be needed to determine whether lifelong clopidogrel therapy is required
in patients with drug-eluting coronary artery stents.
Effect of hypobaric hypoxia, simulating conditions during long-haul
air travel, on coagulation, fibrinolysis, platelet function, and endothe-
lial activation
Toff WD, Jones CI, Ford I, et al. JAMA 2006;295:2251-61.
Conclusion: Hypobaric hypoxia at the levels encountered during
long-haul air travel does not result in prothrombotic conditions in healthy
individuals at low risk of venous thromboembolism.
Summary: There is a proposed link between long-haul air travel and
venous thromboembolism (VTE). The mechanism by which long-haul air
travel may result in VTE is unknown. It is postulated reduced cabin pressure
and reduced oxygen tension may result in an increase risk of VTE compared
with seated immobility. The authors sought to determine whether levels of
hypobaric hypoxia encountered during air travel could activate hemostasis.
This was a single, blind, crossover study performed in a hyperbaric chamber.
The authors assessed the effect of 8 hours of seated exposure to hypobaric
hypoxia in 73 healthy volunteers. The study was conducted in the United
Kingdom from September 2003 to November 2005. The patients were
screened before study enrollment for factor V Leiden mutation and the
prothrombin gene 20210A mutation. If such a mutation was present, they
were excluded. Activation of hemostasis was tested by blood draws before
and after induction of hypobaric hypoxia. Study subjects were exposed
alternatively (1 week apart) to hypobaric hypoxia at conditions similar to
those of commercial air travel and to normal baric, normal hypoxia condi-
tions equivalent to atmospheric conditions at approximately 70 meters
above sea level. Changes in coagulation activity, fibrinolysis, platelet activa-
tion, and endothelial cell activation were then compared under the two
testing conditions. Changes were observed in some hemostatic markers
during normal baric exposure. This was attributed to prolonged sitting and
circadian variation. Including analysis for thrombin-antithrombin complex,
prothrombin fragment, D-dimer, and tests of endogenous thrombin poten-
tial, there were no significant differences between changes in the hypobaric
and normal baric exposures.
Comment: It is important to recognize who was studied and who was
not studied in this investigation. Patients taking oral contraceptive pills were
included, as were patients50 years of age.However, individuals with factor
V Leiden and prothrombin genemutation were excluded, as were those with
a history of VTE. Thus, the patients at highest risk for VTE associated with
long-haul air travel were not studied. The study addresses potential changes
in coagulation induced by hypobaric hypoxic. It does not address the clinical
question of potential coagulation changes in individuals at most risk for
long-haul air travel associated VTE.
Midterm results of extensive primary repair of the thoracic aorta by
means of total arch replacement with open stent graft placement for
acute type A aortic dissection
Uchida N, Ishihara H, Shibamura H, et al. Journal of Thoracic and Cardio-
vascular Surgery 2006;131:862-7.
Conclusion: In patients with acute type A dissection primary repair of
the aorta that includes the aortic arch and the descending thoracic aorta can
be performed in a single stage with a combination of standard synthetic
grafts and self expanding stent grafts.
Summary: Acute type A dissection of the aorta frequently necessitates
emergent surgical treatment. This treatment is often limited to the region of
the ascending aorta and aortic arch leaving a false lumen distally that can
expand and/or rupture. In this paper the authors describe 35 subjects who
received aortic arch replacement and treatment of the descending thoracic
aorta using a combination of a synthetic graft for replacement of the aortic
arch and a stent graft for treatment of the descending thoracic aorta. The
patients were treated between December 1997, and April 2002. There was
a mean followup of 55 months (range, 30-83 months). CT scans were
performed at 1, 3, 12, and 36 months postoperatively in an effort to
document obliteration of the false lumen and exclusion by the stent graft.
Two patients died at the initial procedure secondary to bleeding
and/or low cardiac output. The mean cardio pulmonary bypass time was
175  41 minutes and mean operative time was 338  86 minutes. There
were 13 men and 22 women with a mean age of 67.8 years (range 47-80
years). The aortic arch was reconstructed under conditions of hypothermic
circulatory arrest with re-implantation of the innominate artery, the left
common carotid artery and left subclavian artery using synthetic grafts.
Distally, a stent graft was placed in a 30 French introducer and inserted into
the true lumen of the decending thoracic aortia via the median sternotomy
incision. The graft was fixed in the true lumen of the descending aorta by
expansion of the Z stent and aortic blood pressure. Proximally, the stent
graft was sewn to the dital end of the aortic arch replacement.
Themean diameter of the stent grafts was 26.2mm. Themean length of
the stent grafts was 8.9cm. The technique resulted in obliteration of the false
lumen at the distal edge of the graft in all patients. False lumen obliteration
was also achieved in 65% of the patients at the diaphragmatic level and in 48%
of the patients at the SMA level. Mean enlargement of the whole aorta at the
level of the SMA from 1-36 months postoperatively was 0.375mm (range,
0-2mm). Mean enlargement of the entire aorta at the level of the diaphram
from 1-36 months postoperatively was only (0.5mm range, 0-2mm). Para-
plegia and intestinal ischemia did not occur. No patients required additional
surgical treatment of the thoracoabdominal aorta after discharge from the
hospital.
Comment: This is a clever use of the combination of endovascular and
open surgery. It is essentially a 1-step elephant trunk procedure. The
technique appears to represent a significant advance over 2-stage open repair
of type A aortic dissection. Hopefully this approach can significantly reduce
the number of patients requiring late descending thoracic aortic repair
following repair of type A dissection.
The prevalence of thrombophilia in patients with symptomatic periph-
eral vascular disease
Big S, Chitolie A, Bevan D, et al. Br J Surg 2006;93:577-81.
Conclusion:One third of patients with peripheral vascular disease have
hyperhomocysteinemia and one quarter have evidence of thrombophilia.
Summary: This was a screening study of patients with peripheral
arterial disease (PAD) that was designed to establish the prevalence of
thrombophilia and hyperhomocysteinemia in PAD patients. Between No-
vember 1998 and January 2000, 150 consecutive patients with chronic leg
ischemia were recruited for the study. All had an ankle-brachial index (ABI)
0.8. Also recruited were 25 age-matched controls without PAD (ABI
0.9). Patients and controls underwent thrombophilia screening that in-
cluded protein C and protein S, antithrombin, activated protein C resis-
tance, factor V Leiden, prothrombin gene mutation, and lupus anticoagu-
lant. Fasting homocysteine levels were also determined. A thrombophilia
defect was found in 27.3% of patients (n  41). The most common defect
was protein S deficiency found in 11.3% (n  17). Other detected throm-
bophilias included factor V Leiden mutation in 6.7% (n  10), protein C
deficiency in 4.0% (n  6), and lupus anticoagulant and prothrombin gene
mutation, both found in 4.0%. One patient had antithrombin deficiency.
With single variable analysis, only the presence of critical limb ischemia was
associated with positive thrombophilia (P  .03). Hyperhomocysteinemia
was present in 37.3% of the population. The prevalence of thrombophilia
exceeded that of the control group. The prevalence of hyperhomocysteine-
mia in the patients was double that of the control group.
Comment: The prevalence of various thrombophilias in PAD patients
found in this report is similar to that of previous reports. The exception is the
extraordinarily high prevalence of protein S deficiency in the current study.
The authors suggest this may be result of an acquired protein S deficiency
perhaps influenced by age, sex, and smoking. However, the same risk factors
are prevalent in previous articles on thrombophilia in patients with PAD that
did not find nearly the same level of protein S deficiency. One must question
the author’s assay or standards for abnormality with respect to this particular
thrombophilia. It was noted once again that there is a high prevalence of
hyperhomocysteinemia in patients with PAD. Unfortunately, there still
exists no evidence that treatment of hyperhomocysteinemia in patients with
PAD lowers the end points of cardiovascular events or cardiovascular mor-
tality.
Endovenous treatment of the greater saphenous vein using a 1,320 nm
Nd:YAG laser causes fewer side effects than using a 940 nm diode laser
Proebstle TM, Moehler T, Gul D. Dermatologic Surg 2005;31:1678-84.
Conclusion: Endoluminal laser therapy (ELT) of the greater saphe-
nous vein (GSV) with a 1320-nm neodymium:yttrium-aluminum-garnet
(Nd:YAG) laser results in fewer side effects compared with 940-nm diode
laser ELT.
Summary: ELT of the GSV generally results in some perforation of the
GSV and therefore direct impact to perivenous tissues. Energy absorption
varies with laser wavelength. The authors tested the theory that a 1320-nm
Nd:YAG laser device would result in fewer perioperative side effects. Lasers
with wavelengths strongly absorbed by hemoglobin can result in areas of
sharply increased temperature within the GSV during ELT, resulting in vein
perforations and damage to perivenous tissue. More uniform heating may
occur using wavelengths such as 1320 nm that primarily target water in the
vein wall and therefore, theoretically, do not result in focal areas of sharply
increased temperature leading to perforation and damage to perivenous
tissues. The authors tested this concept by comparing three patient cohorts
receiving ELT of the GSV. In group A, a 940-nm diode laser at 15 W was
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used. In group B, a 940-nm diode laser at 30 W was used. In group C, a
1320-nm laser at 8Wwas used. Laser energy was administered continuously
with constant pullback under tumescent local anesthesia. There were 113
GSVs treated in group A, 136 in group B, and 33 in group C. Average linear
endovenous energy densities of 24, 64, and 62 J/cm and an average
endovenous fluence equivalent of 12, 30, and 33 J/cm2 were administered
to the GSVs respectively. At day 1, occlusion rates were 95% in group A,
100% in group B, and 100% in group C. At 3 months, occlusion rates were
90.3% in group A, 100% in group B, and 97% in group C. Treatment-related
pain (50%) and need for analgesics (36%) were lower in group C compared
with treatment-related pain (81%) and need for analgesics (67%) in the
patients in group B (P  .005. There was also less ecchymosis in group C
compared with group B (P  .05).
Comment: Use of 810-nm ELT devices can result in temperatures up
to 1200°C in animal models (Dermatologic Surgery 2002; 28:56-61). The
goal of ELT of the GSV is closure of the GSV with a minimal amount of
energy so as to result in minimization of damaged perivenous tissues. It may
be that the8W of energy utilized in this study is also effective in achieving
GSV ablation with further reduction in postoperative pain (please see
comment by Dr. Robert Weiss accompanying this article.)
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